FDA approves adrabetadex for Niemann-Pick disease type CThe FDA approved adrabetadex for Niemann-Pick disease type C, a rare fatal genetic disorder, after treated patients showed longer survival compared to external controls.Nov 18, 2026·2 sourcesDrug safetyDrug Policy, Pricing & ApprovalGenetic disordersNeurodegenerative diseaseRare diseasesFDA drug approvalIntrathecalOrphan drug designation00